Allergic rhinitis drugs include antihistamines and intranasal corticosteroids used to control the symptoms of allergic rhinitis, as well as allergen-based immunotherapy offering long-term symptom relief. The market for allergic rhinitis drugs is mature and many generic drugs are available, but some growth areas remain, particularly in key markets where immunotherapy is set to expand. Merck & Co., the leading company by revenue in this market, has collaborated with leading immunotherapy company ALK-Abelló to launch its sublingual immunotherapy tablets Grastek and Ragwitek in the US market, and the pipeline for allergic rhinitis immunotherapy is particularly strong.
Thomas Ling, a senior pharmaceutical and medical devices industry analyst and consultant in visiongain, said: “Growth prospects in the allergic rhinitis drugs market are currently limited due to generic competition in the oral antihistamines and intranasal corticosteroid segments of the market, but opportunities remain, including expansion of immunotherapy in emerging markets, combination drug products such as Meda’s Dymista, and Rx-to-OTC switching of intranasal corticosteroids in the US market. Manufacturers will need to differentiate their product offerings to capture market share in this competitive market.”
Visiongain’s brand new 274-page report provides revenue forecasts to 2024 for the world allergic rhinitis drugs market and leading submarkets. It forecasts sales for the oral antihistamines, intranasal corticosteroids, intranasal antihistamines and immunotherapy segments of the market from 2014 to 2024. Additionally, the report provides revenue forecasts for 26 leading products in the market from 2014 to 2024.
The report also profiles eight leading companies in the allergic rhinitis drugs market – ALK-Abelló, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Sanofi, Stallergenes and UCB, including allergic rhinitis drugs revenue forecasts from 2014 to 2024 for each company. Moreover, the report forecasts allergic rhinitis drugs sales in 12 leading national markets including US, China, Japan, Germany, France, UK, Italy, Spain, Russia, India, Brazil, Mexico and Rest of the World from 2014 to 2024.
It also discusses key marketed products, products in the development pipeline, commercial news, and analysis of strengths, weaknesses, opportunities and threats. It includes interviews with 5 industry experts regarding current market trends. The report also includes a Porter’s Five Forces analysis to understand the degree of competitiveness in this market.
Allergic Rhinitis Drugs Market Forecast 2014-2024: Future Prospects for Companies in Antihistamines, Corticosteroids, Immunotherapy & Vaccines adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on sara.peerun@
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.